Why the study?
Does irbesartan improve outcomes in patients with heart failure and a preserved left ventricular ejection fraction?
Does irbesartan improve outcomes in patients with heart failure and a preserved left ventricular ejection fraction?
Irbesartan does not improve outcomes in patients with heart failure and preserved ejection fraction.
Answers are grounded in this paper and cite their sources.
No support for irbesartan in HFpEF from this cohort; leaves open ARB efficacy pending randomized trials.
Irbesartan did not improve the outcomes of patients with heart failure and a preserved left ventricular ejection fraction. (ClinicalTrials.gov number, NCT00095238.)
No takes yet. Share an insight, caveat, or question.
Massie et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: